Sahajanand Medical & SFC Environmental Line Up IPOs in India
By Business Desk
Sahajanand Medical Technologies and SFC Environmental Technologies prepare for upcoming mainboard IPOs in India, filing for public share sales.
Two prominent Indian companies are advancing their plans to hit the primary market with upcoming initial public offerings. Sahajanand Medical Technologies and SFC Environmental Technologies are preparing public share sales to raise capital and restructure existing holdings.
Sahajanand Medical Technologies IPO Structure
Sahajanand Medical Technologies received SEBI approval on November 17, 2025, for a public issue structured entirely as an offer for sale. The offering involves up to 27,644,231 equity shares from existing investors and promoters. Because it is a pure offer for sale, the Surat-headquartered medical device maker will not receive direct capital proceeds from the issue.
- Filing Date: July 25, 2025 (DRHP)
- SEBI Approval: November 17, 2025
- OFS Shares: 27,644,231 equity shares
- FY25 Revenue: ₹1,035.96 crore
- FY25 Profit After Tax: ₹25.15 crore
For the fiscal year ending March 31, 2025, the company posted a profit after tax of ₹25.15 crore on revenue from operations of ₹1,035.96 crore. This marked a recovery from a net loss of ₹7.35 crore recorded in the previous fiscal year. Lead managers handling the process include Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities, and Nuvama Wealth Management.
SFC Environmental Technologies Funding Plans
SFC Environmental Technologies is moving forward with a mainboard initial public offering consisting of a fresh issue and promoter shares. The wastewater treatment firm is preparing to tap the market alongside other upcoming issues.
- Fresh Issue: ₹185 crore
- Promoter OFS: 1.08 crore shares
- Pre-IPO Placement Potential: ₹37 crore
- Order Book Value: ₹6,314.93 million (as of September 2024)
The company plans to use the fresh capital primarily to repay debt for itself and its subsidiary, Vasudha Waste Treatment Private Limited. Additional funds from the offering are earmarked for working capital requirements and general corporate purposes.